- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
March 3rd, 2005
On Monday, Elan's (ELN) stock price dropped 70 percent on news that the company was pulling its highly touted and promising new treatment for multiple sclerosis, Tysabri, because two patients using the treatment had developed a rare nervous-system disorder. In the ensuing panic, the company lost billions in market capitalization and was downgraded by a few investment houses.
The drop may represent a real opportunity for investors who have a long-term perspective and understand the company's Nanocrystal technology.
|Related News Press|
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016